Involvement of type A monoamine oxidase in neurodegeneration: regulation of mitochondrial signaling leading to cell death or neuroprotection.
In neurodegenerative diseases, including Parkinson's and Alzheimer's diseases, apoptosis is a common type of cell death, and mitochondria emerge as the major organelle to initiate death cascade. Monoamine oxidase (MAO) in the mitochondrial outer membrane produces hydrogen peroxide by oxidation of monoamine substrates, and induces oxidative stress resulting in neuronal degeneration. On the other hand, a series of inhibitors of type B MAO (MAO-B) protect neurons from cell death. These results suggest that MAO may be involved in the cell death process initiated in mitochondria. However, the direct involvement of MAO in the apoptotic signaling has been scarcely reported. In this paper, we present our recent results on the role of MAO in activating and regulating cell death processing in mitochondria. Type A MAO (MAO-A) was found to bind an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol, and induce apoptosis in dopaminergic SH-SY5Y cells containing only MAO-A. To examine the intervention of MAO-B in apoptotic process, human MAO-B cDNA was transfected to SH-SY5Y cells, but the sensitivity to N-methyl(R)salsolinol was not affected, even though the activity and protein of MAO-B were expressed markedly. MAO-B oxidized dopamine with production of hydrogen peroxide, whereas in control cells expressing only MAO-A, dopamine autoxidation produced superoxide and dopamine-quinone, and induced mitochondrial permeability transition and apoptosis. Rasagiline and other MAO-B inhibitors prevent the activation of apoptotic cascade and induce prosurvival genes, such as bcl-2 and glial cell line-derived neurotrophic factor, in MAO-A-containing cells. These results demonstrate a novel function of MAO-A in the induction and regulation of apoptosis. Future studies will clarify more detailed mechanism behind regulation of mitochondrial death signaling by MAO-A, and bring out new strategies to cure or ameliorate the decline of neurons in neurodegenerative disorders.
Naoi
M
M
Department of Neurosciences, Gifu International Institute of Biotechnology, Kakamigahara, Gifu, Japan. mnaoi@giib.or.jp
Maruyama
W
W
Akao
Y
Y
Yi
H
H
Yamaoka
Y
Y
D016923:Cell Death / Q000187:drug effects; D045744:Cell Line, Tumor; D004298:Dopamine / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004789:Enzyme Activation / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005786:Gene Expression Regulation / Q000187:drug effects; D006801:Humans; D007189:Indans / Q000494:pharmacology; D008928:Mitochondria / Q000187:drug effects / Q000201:enzymology*; D051336:Mitochondrial Membranes / Q000187:drug effects* / Q000201:enzymology; D008995:Monoamine Oxidase / Q000235:genetics / Q000378:metabolism*; D009410:Nerve Degeneration / Q000201:enzymology*; D009447:Neuroblastoma; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D034741:RNA, Small Interfering / Q000494:pharmacology; D012490:Salsoline Alkaloids / Q000494:pharmacology; D012701:Serotonin / Q000494:pharmacology; D015398:Signal Transduction / Q000528:radiation effects*; D044005:Tetrahydroisoquinolines / Q000494:pharmacology; D014162:Transfection / Q000379:methods
D004791:Enzyme Inhibitors; D007189:Indans; D019253:Proto-Oncogene Proteins c-bcl-2; D034741:RNA, Small Interfering; D012490:Salsoline Alkaloids; D044005:Tetrahydroisoquinolines; C031967:rasagiline; D012701:Serotonin; C032837:salsoline; D008995:Monoamine Oxidase; D004298:Dopamine